NASDAQ:WINT Windtree Therapeutics (WINT) Stock Price, News & Analysis $0.01 0.00 (-2.94%) As of 07/17/2026 03:52 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About Windtree Therapeutics Stock (NASDAQ:WINT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Windtree Therapeutics alerts:Sign Up Key Stats Today's Range$0.0132▼$0.015750-Day Range$0.01▼$0.0252-Week Range$0.01▼$1.35Volume37,629 shsAverage Volume292,617 shsMarket Capitalization$593.84 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Windtree Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative therapies for acute cardiovascular and pulmonary conditions. The company leverages its proprietary KL4 surfactant technology to address diseases marked by surfactant deficiency or dysfunction, with a primary focus on acute respiratory distress syndrome (ARDS) in adults and respiratory distress syndrome (RDS) in premature infants. The company’s lead platform comprises synthetic peptide‐based surfactants designed to restore lung function by reducing surface tension in the alveoli. Windtree’s pipeline includes aerosolized and intratracheal formulations intended for rapid distribution in the lung, including programs that have advanced through preclinical studies and early-stage clinical trials. These programs aim to offer an alternative to animal-derived surfactants and to target patient populations with significant unmet medical needs. Headquartered in Warrington, Pennsylvania, Windtree collaborates with academic research centers and clinical investigators across the United States and Europe to conduct its development programs. The company’s activities encompass formulation optimization, toxicology testing, and multi-site clinical evaluations, supported by partnerships that extend its reach into critical care and neonatal intensive care settings. Under the leadership of President and CEO Michael Ott, Windtree maintains a management team with extensive experience in drug development, regulatory affairs and commercial strategy. The organization is committed to advancing its pipeline through regulatory interactions and clinical milestones in pursuit of therapies that can improve outcomes for patients with serious cardiopulmonary disorders.AI Generated. May Contain Errors. Read More Receive WINT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Windtree Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WINT Stock News HeadlinesWindtree Therapeutics Delays Filing of Annual ReportApril 1, 2026 | tipranks.comCommLoan Achieves Nationwide Regulatory Approval Across All 50 StatesMarch 17, 2026 | prnewswire.comThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong. Dave Aquino's 0DTE Playbook breaks down a step-by-step strategy designed for shorter risk exposure, clear entry and exit windows, and faster feedback - no chart-watching required.July 18 at 1:00 AM | Base Camp Trading (Ad)Windtree Therapeutics Announces Sudden Departure of President and COOJanuary 17, 2026 | theglobeandmail.comWindtree sells heart drug assets, keeps a cut of any future breakthroughDecember 30, 2025 | msn.comWindtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug CandidatesDecember 23, 2025 | finance.yahoo.comWindtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech SpaceDecember 4, 2025 | markets.businessinsider.comWindtree announces it has signed a letter of intent to acquire CommLoanDecember 4, 2025 | msn.comSee More Headlines WINT Stock Analysis - Frequently Asked Questions How have WINT shares performed this year? Windtree Therapeutics' stock was trading at $0.0320 at the beginning of the year. Since then, WINT shares have decreased by 58.8% and is now trading at $0.0132. How were Windtree Therapeutics' earnings last quarter? Windtree Therapeutics, Inc. (NASDAQ:WINT) announced its quarterly earnings data on Tuesday, August, 19th. The company reported ($3.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($99.00) by $95.94. When did Windtree Therapeutics' stock split? Windtree Therapeutics's stock reverse split on Friday, February 21st 2025.The 1-50 reverse split was announced on Tuesday, February 18th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Windtree Therapeutics? Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Windtree Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Windtree Therapeutics investors own include Plug Power (PLUG), Trevena (TRVN), SNDL (SNDL), AMC Entertainment (AMC), Sphere 3D (ANY), BioCardia (BCDA) and Sonnet BioTherapeutics (SONN). Company Calendar Last Earnings8/19/2025Today7/18/2026Next Earnings (Estimated)8/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:WINT CIK946486 Webwww.windtreetx.com Phone(215) 488-9300Fax215-488-9301Employees30Year Founded1992Profitability EPS (Trailing Twelve Months)($8.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-207.34% Return on Assets-50.19% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book0.01Miscellaneous Outstanding Shares44,988,000Free Float3,656,000Market Cap$593.84 thousand OptionableNot Optionable Beta1.55 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:WINT) was last updated on 7/18/2026 by MarketBeat.com Staff. From Our PartnersCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | Sponsored3 AI stocks to buy before August 2026Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
